Compare
Idexx Laboratories Inc vs QuidelOrtho Corp vs Neogen Corp vs Intellia Therapeutics, Inc.
| Latest fiscal year | Idexx Laboratories Inc IDXX | QuidelOrtho Corp QDEL | Neogen Corp NEOG | Intellia Therapeutics, Inc. NTLA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-28 | 2026-05-31 | 2025-12-31 |
| Revenue | $4.30B | $2.73B | $870.40M | $67.67M |
| Revenue growth (YoY) | +10.4% | -1.9% | -2.7% | +16.9% |
| Gross margin | 61.8% | n/a | 46.9% | n/a |
| Operating margin | 31.6% | -33.7% | -2.5% | -651.7% |
| Net margin | 24.6% | -41.5% | -0.9% | -609.9% |
| Net income | $1.06B | -$1.13B | -$7.90M | -$412.69M |
| EPS (Diluted) | $13.08 | -$16.69 | -$0.04 | -$3.81 |
| Operating cash flow | $1.18B | $105.20M | $83.20M | -$394.74M |
| Free cash flow | $1.06B | -$83.00M | $31.90M | -$395.87M |
| Cash & equivalents | $180.07M | $169.80M | $185.50M | $155.46M |
| Total assets | $3.35B | $5.77B | $3.35B | $842.13M |
| Total liabilities | $1.75B | $3.85B | $1.25B | $170.73M |
| Shareholders' equity | $1.61B | $1.92B | $2.09B | $671.39M |
| Return on year-end equity | 66.0% | -58.9% | -0.4% | -61.5% |
| Shares outstanding | 79.71M | 67.90M | 217.70M | 116.32M |
Revenue, most recent five fiscal years
| Fiscal year | Idexx Laboratories Inc | QuidelOrtho Corp | Neogen Corp | Intellia Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $4.30B Ended 2025-12-31 | $2.73B Ended 2025-12-28 | $870.40M Ended 2026-05-31 | $67.67M Ended 2025-12-31 |
| 1 year earlier | $3.90B Ended 2024-12-31 | $2.78B Ended 2024-12-29 | $894.70M Ended 2025-05-31 | $57.88M Ended 2024-12-31 |
| 2 years earlier | $3.66B Ended 2023-12-31 | $3.00B Ended 2023-12-31 | $924.20M Ended 2024-05-31 | $36.27M Ended 2023-12-31 |
| 3 years earlier | $3.37B Ended 2022-12-31 | $3.27B Ended 2023-01-01 | $822.45M Ended 2023-05-31 | $52.12M Ended 2022-12-31 |
| 4 years earlier | $3.22B Ended 2021-12-31 | $1.70B Ended 2022-01-02 | $527.16M Ended 2022-05-31 | $33.05M Ended 2021-12-31 |